- Home
- OTLY vs CMPX Comparison
OTLY vs CMPX Comparison
Compare OTLY & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- CMPX
- Stock Information
- Founded
- OTLY 1994
- CMPX 2014
- Country
- OTLY Sweden
- CMPX United States
- Employees
- OTLY N/A
- CMPX N/A
- Industry
- OTLY Packaged Foods
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- OTLY Consumer Staples
- CMPX Health Care
- Exchange
- OTLY Nasdaq
- CMPX Nasdaq
- Market Cap
- OTLY 303.5M
- CMPX 291.8M
- IPO Year
- OTLY 2021
- CMPX N/A
- Fundamental
- Price
- OTLY $13.09
- CMPX $2.65
- Analyst Decision
- OTLY Buy
- CMPX Strong Buy
- Analyst Count
- OTLY 5
- CMPX 9
- Target Price
- OTLY $18.40
- CMPX $12.67
- AVG Volume (30 Days)
- OTLY 89.3K
- CMPX 797.6K
- Earning Date
- OTLY 07-23-2025
- CMPX 08-11-2025
- Dividend Yield
- OTLY N/A
- CMPX N/A
- EPS Growth
- OTLY N/A
- CMPX N/A
- EPS
- OTLY N/A
- CMPX N/A
- Revenue
- OTLY $822,041,000.00
- CMPX $850,000.00
- Revenue This Year
- OTLY $4.31
- CMPX N/A
- Revenue Next Year
- OTLY $5.01
- CMPX N/A
- P/E Ratio
- OTLY N/A
- CMPX N/A
- Revenue Growth
- OTLY 4.47
- CMPX N/A
- 52 Week Low
- OTLY $6.00
- CMPX $0.87
- 52 Week High
- OTLY $23.40
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- OTLY 61.02
- CMPX 64.52
- Support Level
- OTLY $12.27
- CMPX $2.62
- Resistance Level
- OTLY $13.50
- CMPX $2.87
- Average True Range (ATR)
- OTLY 0.65
- CMPX 0.16
- MACD
- OTLY 0.01
- CMPX 0.00
- Stochastic Oscillator
- OTLY 78.93
- CMPX 81.03
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.